deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01229865

Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics

Conditions Differential Thyroid Cancer
Interventions VB-111
Updated 8 times since 2017 Last updated: Oct 22, 2018 Started: Dec 31, 2010 Primary completion: Oct 31, 2014 Completion: Jun 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Differential Thyroid Cancer and is currently completed. Vascular Biogenics Ltd. operating as VBL Therapeutics leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotActive Not Recruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotUnknown Status~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotUnknown Status~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  5. Jun 2018 — Nov 2018 [monthly]

    Unknown Status PHASE2

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  2. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vascular Biogenics Ltd. operating as VBL Therapeutics
Data source: Vascular Biogenics Ltd. operating as VBL Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations